Related Articles
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets
Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein
MHC class I down-regulation: tumour escape from immune surveillance? (Review)
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours